{"id":"W4405038457","doi":"10.1182/blood-2024-201543","title":"Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada); University of Alberta","funders":"","keywords":"Daratumumab; Bortezomib; Dexamethasone; Medicine; Internal medicine; Oncology; Multiple myeloma; Minimal residual disease; Refractory (planetary science); Carfilzomib; Bone marrow; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00444308,0.000644808,0.002167086,0.0002936989,0.0003074571,0.001118265,0.0008428174,0.0008637827,0.001390708],"category_scores_gemma":[0.002836427,0.0003189241,0.003110833,0.0004107724,0.0008476648,0.0007596101,0.0006578141,0.002046497,0.0003053012],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001118448,"about_ca_system_score_gemma":0.0008985247,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004959428,"about_ca_topic_score_gemma":0.001586845,"domain_scores_codex":[0.998085,0.001172653,0.0001711481,0.0002750589,0.0001511179,0.0001450923],"domain_scores_gemma":[0.9980136,0.0006290887,0.0006315795,0.0001724715,0.00008608781,0.0004670779],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9017751,0.003359386,0.04725267,0.001132678,0.008714759,0.00007930664,0.0001622064,0.001691611,0.003732298,0.0002739861,0.001788745,0.03003721],"study_design_scores_gemma":[0.5739081,0.2144834,0.1831657,0.000335946,0.01394108,0.0006200761,0.0002301035,0.00323253,0.00293241,0.00163702,0.005393743,0.0001199235],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919174,0.005931884,0.0000983093,0.000345831,0.00006964588,0.0002339911,0.0007229332,0.0000111036,0.0006689732],"genre_scores_gemma":[0.996666,0.0007895642,0.0002254519,0.0003420204,0.0000993158,0.0002967464,0.00131168,0.00000491523,0.000264184],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00444308,"threshold_uncertainty_score":0.02349752,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01483032040813998,"score_gpt":0.2691273837767051,"score_spread":0.2542970633685652,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}